Author/Authors :
Yazılıta, Fatma Ankara Dr. Sami Ulus Maternity and Children Hospital Pediatric - Nephrology and Rheumatology Department, Ankara, Turkey , Özdel, Semanur Ankara Dr. Sami Ulus Maternity and Children Hospital Pediatric - Nephrology and Rheumatology Department, Ankara, Turkey , Simsek, Dogan Ankara Dr. Sami Ulus Maternity and Children Hospital Pediatric - Nephrology and Rheumatology Department, Ankara, Turkey , Baglan, Esra Ankara Dr. Sami Ulus Maternity and Children Hospital Pediatric - Nephrology and Rheumatology Department, Ankara, Turkey , Bülbül, Mehmet Ankara Dr. Sami Ulus Maternity and Children Hospital Pediatric - Nephrology and Rheumatology Department, Ankara, Turkey
Abstract :
Objectives: This study aimed to determine the reliability of novel markers of treatment response in children with familial Mediterranean
fever receiving canakinumab treatment, as compared to conventional inflammatory indexes
Methods: Clinical and laboratory data for 19 colchicine-resistant Familial Mediterranean Fever patients treated with canakinumab
were retrospectively reviewed. Patients with systemic diseases other than familial Mediterranean fever and familial Mediterranean
fever related complications were excluded from the study.
Results: Following canakinumab treatment there was a non-significant decrease in the neutrophil/ lymphocyte ratio (P = 0.523)
and a significant decrease in the platelet/lymphocyte ratio (P = 0.003). There wasn no significant difference in mean platelet volume
before and after canakinumab treatment (P = 0.762).
Conclusions: The present findings indicate that the platelet/lymphocyte ratio could be considered a more reliable marker than
the neutrophil/lymphocyte ratio of response to canakinumab therapy in patients with colchicine-resistant familial Mediterranean
fever.
